Condition: Primary CNS Lymphoma (PCNSL) · Sponsor: The Lymphoma Academic Research Organisation
The purpose of this phase 2 study is to evaluate the efficacy and safety of epcoritamab in subjects with relapsed or refractory primary diffuse large B-cell lymphoma of the Central Nervous System treated with rituximab and lenalidomide.
This description comes directly from the study's public registry record.
Project Management · 04 72 66 93 33 · e-revri@lysarc.org
Always discuss trial participation with your own doctor first.
| INSTITUT BERGONIE - Service d'Oncologie Médicale | Bordeaux, France | Recruiting |
| INSTITUT D'HEMATOLOGIE DE BASSE NORMANDIE - Service Hématologie | Caen, France | Recruiting |
| CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique | Clermont-Ferrand, France | Recruiting |
| CHU DE LILLE - HOPITAL CLAUDE HURIEZ - Service des Maladies du Sang | Lille, France | Recruiting |
| CHR DE MARSEILLE - CHU TIMONE - Service de Neuro-Oncologie | Marseille, France | Active Not Recruiting |
| CHRU DE NANCY - HOPITAL CENTRAL - Service de Neurologie | Nancy, France | Active Not Recruiting |
| GHU PITIE-SALPETRIERE - CHARLES FOIX - Service Neurologie | Paris, France | Recruiting |
| HOPITAL DE LA PITIE SALPETRIERE - Service Hématologie Clinique | Paris, France | Active Not Recruiting |
| CHU LYON-SUD - Hématologie Clinique | Pierre-Bénite, France | Recruiting |
| CHU PONTCHAILLOU - Hématologie Clinique | Rennes, France | Active Not Recruiting |
| INSTITUT CURIE - SITE SAINT-CLOUD - Service Hématologie | Saint-Cloud, France | Recruiting |
| IUCT ONCOPOLE - Service Hématologie | Toulouse, France | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06931652